Sinovac Biotech has licensed the Biolik Biopharmaceutical Company, a Ukraine-located vaccine manufacturer, to conduct clinical trials of Healive®, Sinovac’s inactivated hepatitis A vaccine, in the Ukraine. Biolik, which will market and distribute Healive in the Ukraine after it obtains regulatory clearance, estimates the eventual market for Healive in the Ukraine at $10 million annually. Thus far in its corporate history, Sinovac has not been aggressive in promoting its products outside of China. More details...

Stock Symbol: (AMEX: SVA)